Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Applied Genetic Technologies Corporation AGTC
$0.39
На 13:45, 16 марта 2023
+1 182.05%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
0.00000000
-
week52high
2.83
-
week52low
0.23
-
Revenue
325000
-
P/E TTM
0
-
Beta
1.58360500
-
EPS
-1.46000000
-
Last Dividend
0.00000000
-
Next Earnings Date
13 февр 2023 г. в 05:00
Описание компании
Applied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops transformational genetic therapies for patients suffering from rare and debilitating diseases. Its advanced product candidates include three ophthalmology development programs across two targets, including X-linked retinitis pigmentosa, which is in the Phase I/II clinical trials; and achromatopsia that is in Phase I/II clinical trials. It is also developing an optogenetic product candidate to treat advanced retinal disease. In addition, the company has initiated one preclinical program in otology; and two preclinical programs in targeting central nervous system disorders, including frontotemporal dementia and amyotrophic lateral sclerosis. It has collaboration agreements with University of Florida; Bionic Sight, LLC; and Otonomy, Inc. Applied Genetic Technologies Corporation was incorporated in 1999 and is headquartered in Alachua, Florida.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Chardan Capital | Buy | Buy | 18 мая 2022 г. |
| BTIG | Buy | 15 июн 2021 г. | |
| Stifel | Buy | 02 мар 2021 г. | |
| Roth Capital | Buy | Buy | 01 февр 2021 г. |
| Roth Capital | Buy | Buy | 17 ноя 2020 г. |
| Stifel | Buy | Buy | 30 сент 2022 г. |
| HC Wainwright & Co. | Buy | Buy | 30 сент 2022 г. |
| BTIG | Neutral | Buy | 29 сент 2022 г. |
| Chardan Capital | Buy | Buy | 28 сент 2022 г. |
| Wells Fargo | Equal-Weight | Overweight | 04 окт 2022 г. |
| Wells Fargo | Equal-Weight | Equal-Weight | 25 окт 2022 г. |
| HC Wainwright & Co. | Neutral | Buy | 25 окт 2022 г. |
| Wedbush | Neutral | Outperform | 24 окт 2022 г. |
| Stifel | Hold | Buy | 24 окт 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Rosen James | D | 0 | 14000 | 30 ноя 2022 г. |
| Rosen James | D | 0 | 1000 | 30 ноя 2022 г. |
| VANLENT ANNE | D | 0 | 14000 | 30 ноя 2022 г. |
| Robinson James A. Jr. | D | 0 | 25000 | 30 ноя 2022 г. |
| Aliski William | D | 0 | 14000 | 30 ноя 2022 г. |
| Aliski William | D | 0 | 8500 | 30 ноя 2022 г. |
| Koenig Scott | D | 0 | 14000 | 30 ноя 2022 г. |
| Koenig Scott | D | 0 | 34246 | 30 ноя 2022 г. |
| Hashad Yehia | D | 0 | 14000 | 30 ноя 2022 г. |
| HURWITZ EDWARD | D | 0 | 14000 | 30 ноя 2022 г. |
Новостная лента
Make Money With Penny Stocks in November? 3 Methods to Use
PennyStocks
25 окт 2022 г. в 08:29
Use these tips for profiting with penny stocks The post Make Money With Penny Stocks in November? 3 Methods to Use appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
AGTC to Participate in Upcoming Investor Conferences
GlobeNewsWire
01 сент 2022 г. в 08:00
GAINESVILLE, Fla., and CAMBRIDGE, Mass., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (“AGTC” or the “Company”) (Nasdaq: AGTC), a clinical-stage biotechnology company focused on the development and potential commercialization of adeno-associated virus (AAV)-based gene therapies for the treatment of rare and debilitating diseases with an initial focus on inherited retinal diseases, today announced that management will be participating in the following investor conferences:
AGTC to Participate in Upcoming Investor Conferences
GlobeNewsWire
01 авг 2022 г. в 16:05
GAINESVILLE, Fla. and CAMBRIDGE, Mass., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (“AGTC” or the “Company”) (Nasdaq: AGTC), a clinical-stage biotechnology company focused on the development and potential commercialization of adeno-associated virus (AAV)-based gene therapies for the treatment of rare and debilitating diseases with an initial focus on inherited retinal diseases, today announced that management will be participating in the following investor conferences: